Table 1_Cell cycle pathway alterations predict outcomes post-liver transplantation for hep

91 patients with hepatocellular carcinoma who underwent liver transplantation between 2016 and 2023 had their tumor DNA sequenced for 38 genes. The dataset includes clinical outcomes such as overall survival and recurrence-free survival, linked to molecular alterations grouped into signaling pathways. Ashton A. Connor published this prospective single-center study on figshare in 2026.

Use Cases

• Predicting post-liver transplantation survival based on cell cycle pathway alterations.
• Identifying recurrence patterns (e.g., liver vs. lungs) associated with specific genetic mutations.
• Validating molecular selection criteria for hepatocellular carcinoma using clinical outcome data.
• Analyzing the prevalence of potentially actionable mutations in a transplant cohort.

Strengths

• Includes 91 sequenced patient samples from a cohort of 261 liver transplants for HCC.
• Contains validated outcome metrics: 3-year overall survival rates (90.9% vs. 62.5%) linked to specific pathway alterations.
• Targeted sequencing covers 38 genes relevant to hepatocellular carcinoma.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.
• Data is from a single-center study, which may limit generalizability.

Provenance

Source

figshare, author Ashton A. Connor.

Collection Method

Prospective single-center study; tumor DNA from explanted livers subjected to targeted sequencing.

Time Range

Patients underwent liver transplantation between 11 November 2016 and 4 April 2023.

Freshness

Last updated 2026-04-10 05:59:20; freshness should be verified.

Geography

null